Close X
Attorney Spotlight

How did Mike DeAgro's experience co-founding a nonprofit advocacy organization lead to a career in the legal field? Find out more>


Close X


Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more

Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Highly-Acclaimed U.S. Healthcare Fraud and Enforcement Panel


April 23-25, 2018

Bass, Berry & Sims attorney John Kelly will speak at CBI's 15th Annual Pharmaceutical Compliance Congress. John will speak on a point/counterpoint session titled, "Highly-Acclaimed U.S. Healthcare Fraud and Enforcement Panel." It will be held on Tuesday, April 24, 2018 at 11:00 a.m. and feature current and former prosecutors. The session will delve into recent settlements and on-going investigations with the opportunity to hear directly from regulatory leaders across the nation spearheading the charge against healthcare fraud.

Session topics include:

  • A zero-in on the top areas of focus such as PSPs, charitable contributions, off-label, anti-kickback, pricing transparency and the opioid epidemic
  • Gaining insight into emerging enforcement trends and focal points for 2018
  • Collaborating with manufacturers to decrease non-compliance and improve government relations
  • Discussion on how different government agencies communicate and collaborate
  • Discovering how outside counsel responds to the top priorities of the U.S. government
  • Key takeaways from recent high-profile cases to mitigate risk moving forward

The CBI 15th Annual Pharmaceutical Compliance Congress will be held April 23-25, 2018 at the Ritz-Carlton in Washington, D.C. For more information and registration, visit the CBI website.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.